High Response Incidence Seen for Axatilimab in Recurrent, Refractory GVHD

MONDAY, Sept. 23, 2024-- For patients with recurrent or refractory graft-versus-host disease (GVHD), the colony-stimulating factor 1 receptor (CSF1R)-blocking antibody axatilimab results in a high incidence of overall response, according to a...